Vicept Management, VCs Team Up Again To Launch Aclaris With $21M
This article was originally published in The Pink Sheet Daily
Newly launched dermatology start-up Aclaris brings the band back together, as Vicept’s core management and VCs begin a new endeavor in a sometimes-neglected sector.
You may also be interested in...
Start-Up Quarterly Statistics, Q4 2012
Start-ups raised a total of $670.3 million across all industries in Q4 2012, just $11.6 million less than in Q3, and 90% of that money went to biopharma companies. Several start-up companies inked deals with Big Pharmas, and there were three acquisitions – two in biopharma and one in the device sector.
NeXeption, Not The Rule: Another Twist On Asset-Based Financing
As VCs experiment with new models for single-asset companies, new entrant NeXeption is trying something similar without raising its own fund. Can it wring enough value from the best assets pharmas are neglecting, without giving too much back to their original owners?
Financings Of The Fortnight: Could California’s Regenerative Medicine Ballot Initiative Pass Today?
Plus news on recent financings by bluebird bio, Puma Biotechnology, Atara Biotherapeutics and Aclaris Therapeutics.